1. Home
  2. HGBL vs MAIA Comparison

HGBL vs MAIA Comparison

Compare HGBL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heritage Global Inc.

HGBL

Heritage Global Inc.

HOLD

Current Price

$1.34

Market Cap

46.9M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.97

Market Cap

49.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HGBL
MAIA
Founded
1937
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.9M
49.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
HGBL
MAIA
Price
$1.34
$1.97
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
798.1K
1.3M
Earning Date
03-12-2026
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$49,890,000.00
N/A
Revenue This Year
$16.03
N/A
Revenue Next Year
$5.33
N/A
P/E Ratio
$15.84
N/A
Revenue Growth
0.02
N/A
52 Week Low
$1.21
$0.87
52 Week High
$2.39
$3.19

Technical Indicators

Market Signals
Indicator
HGBL
MAIA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
HGBL
MAIA

About HGBL Heritage Global Inc.

Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: